LDS/Medical Tests/Plasminogen Activator Inhibitor Antigen 1 (PAI-1), Plasma

Plasminogen Activator Inhibitor Antigen 1 (PAI-1), Plasma

PAI-1 is a 43 kDa single-chain glycoprotein and a serine protease inhibitor produced primarily by endothelial cells and hepatocytes. It is also stored in platelet α-granules and released during vascular injury. Circulating PAI-1 binds vitronectin, which stabilizes its active form.

PAI-1 is the principal inhibitor of tissue-type plasminogen activator (tPA) and urokinase (uPA), and therefore plays a central role in regulating fibrinolysis. Although synthesized in an active form, PAI-1 is functionally unstable, with an in vivo half-life of approximately 2 hours.

PAI-1 exists in four conformations:

  • Active (inhibitory)
  • Latent (nonreactive)
  • Substrate (cleavable, non-inhibitory)
  • Cleaved/inert

Elevated PAI-1 levels impair fibrinolysis and are associated with thrombotic risk, including veno-occlusive disease (VOD) following bone marrow transplantation (BMT). PAI-1 antigen has been identified as an independent diagnostic and severity marker of VOD and may help distinguish VOD from other causes of post-transplant hyperbilirubinemia.

Increased PAI-1 levels are also observed in malignancy, liver disease, postoperative states, sepsis, pregnancy (2nd–3rd trimester), obesity, and coronary heart disease.

Reduced or absent active PAI-1 (congenital or acquired) is associated with clinically significant bleeding, including hemarthroses, hematomas, menorrhagia, easy bruising, and postoperative hemorrhage.

  • Evaluation of thrombotic risk
  • Evaluation of deep venous thromboembolism, including women taking oral contraceptives or hormone replacement
  • Evaluation of coronary artery disease and/or stroke
  • Evaluation of recurrent miscarriages
  • Evaluation of pregnancy complications
  • Evaluation of meningococcal sepsis

Positive results are considered if homozygous (4G/4G) or heterozygous (4G/5G or 5G/4G) are detected. The presence of these variations could indicate increase risk in:

  • Deep venous thrombosis
  • Pulmonary embolism
  • Patients with history of recurrent miscarriages
  • Venous thrombosis
  • Stroke
  • Heart attack and stroke
  • Preeclampsia
  • Recurrent miscarriages
  • Pregnancy complications and termination (spontaneous abortion)
  • Cancer

Decreased in:

  • Hyperfibrinolysis resulting from PAI-1 deficiency; this is a rare bleeding disorder

3.1-72.0 ng/mL

Enzyme-Linked Immunosorbent Assay (ELISA). 

Platelet-poor plasma, Light-blue top (3.2% sodium citrate). 

Separate plasma within 4 hour and freeze. 

Stability

  • Ambient: not acceptable
  • Refrigerated: not acceptable 
  • Frozen: up to 30 days
Prothrombin time (PT), Activated Partial Thromboplastin Time (aPTT), CBC, Factor II (prothrombin) Mutation, Factor V Leiden, Methyltetrahydropholate Reductase C677T and A1298C mutation, Protein S activity and antigen, Protein C Activity and antigen, Anticardiolipin Antibody, Antiphospholipid antibody (Lupus anticoagulant), Factor XIII, Coagulation Mixing Study, Platelet Antibody, Anti-Beta 2 Glycoprotein 1, Anti-nuclear antigen (ANA) antibody, PAI-1 activity, PAI-2 antigen.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login